{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:51:53Z","timestamp":1791949913692,"version":"4.3.4"},"reference-count":207,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bbcan.2025.189294","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T16:41:51Z","timestamp":1741279311000},"page":"189294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["CD47 as a potent target in cancer immunotherapy: A review"],"prefix":"10.1016","volume":"1880","author":[{"given":"Hiva","family":"Ahvati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheleh","family":"Roudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Sobhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Safari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2025.189294_bb0005","unstructured":"Siegel, (2024)."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189294_bb0010","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"issue":"6165","key":"10.1016\/j.bbcan.2025.189294_bb0015","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0020","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.982382","article-title":"Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma","volume":"4","author":"Chevolet","year":"2015","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189294_bb0025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/nri2438","article-title":"Immunotherapy of autoimmunity and cancer: the penalty for success","volume":"8","author":"Caspi","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189294_bb0030","first-page":"2043","article-title":"Immunotherapy of solid tumor: perspectives on vaccine and cell therapy","volume":"70","author":"Ikeda","year":"2012","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.bbcan.2025.189294_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189294_bb0040","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRPalpha immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRPalpha-CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol."},{"issue":"2\u20133","key":"10.1016\/j.bbcan.2025.189294_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.seminoncol.2020.05.009","article-title":"Just eat it: a review of CD47 and SIRP-alpha antagonism","volume":"47","author":"Oronsky","year":"2020","journal-title":"Semin. Oncol."},{"issue":"6 Pt 1","key":"10.1016\/j.bbcan.2025.189294_bb0055","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1083\/jcb.111.6.2785","article-title":"Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins","volume":"111","author":"Brown","year":"1990","journal-title":"J. Cell Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0060","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol."},{"issue":"5473","key":"10.1016\/j.bbcan.2025.189294_bb0065","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol. Rev."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0075","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/1042819042000201989","article-title":"Role of CD47 in erythroid cells and in autoimmunity","volume":"45","author":"Oldenborg","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbcan.2025.189294_bb0080","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRPalpha axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri1859","article-title":"The SIRP family of receptors and immune regulation","volume":"6","author":"Barclay","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1074\/jbc.274.2.559","article-title":"Integrin-associated protein is a ligand for the P84 neural adhesion molecule","volume":"274","author":"Jiang","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189294_bb0095","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/1521-4141(2000)30:8<2130::AID-IMMU2130>3.0.CO;2-8","article-title":"CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRP\u03b1 1","volume":"30","author":"Vernon-Wilson","year":"2000","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189294_bb0100","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood.V94.11.3633","article-title":"B\u00fchring, human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47","volume":"94","author":"Seiffert","year":"1999","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189294_bb0105","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood.V97.9.2741","article-title":"Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(\u2212) hematopoietic cells","volume":"97","author":"Seiffert","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189294_bb0110","doi-asserted-by":"crossref","first-page":"10133","DOI":"10.18632\/oncotarget.7100","article-title":"A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer","volume":"7","author":"Kaur","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189294_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221294","article-title":"EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling","volume":"14","author":"Jung","year":"2019","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/cvr\/cvv243","article-title":"HIF-2\u03b1-mediated induction of pulmonary thrombospondin-1 contributes to hypoxia-driven vascular remodelling and vasoconstriction","volume":"109","author":"Labrousse-Arias","year":"2016","journal-title":"Cardiovasc. Res."},{"issue":"45","key":"10.1016\/j.bbcan.2025.189294_bb0125","doi-asserted-by":"crossref","first-page":"E6215","DOI":"10.1073\/pnas.1520032112","article-title":"HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189294_bb0130","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1681\/ASN.2012020137","article-title":"Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury","volume":"23","author":"Rogers","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbcan.2025.189294_bb0135","series-title":"Integrins: An Overview of Structural and Functional Aspects, Madame Curie Bioscience Database [Internet]","author":"Danen","year":"2013"},{"issue":"6621","key":"10.1016\/j.bbcan.2025.189294_bb0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/386181a0","article-title":"A family of proteins that inhibit signalling through tyrosine kinase receptors","volume":"386","author":"Kharitonenkov","year":"1997","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1471-4906(02)02223-8","article-title":"CD200 and membrane protein interactions in the control of myeloid cells","volume":"23","author":"Barclay","year":"2002","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0150","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood-2004-07-2823","article-title":"Adhesion of human T cells to antigen-presenting cells through SIRP\u03b22-CD47 interaction costimulates T-cell proliferation","volume":"105","author":"Piccio","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0155","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood-2008-01-134429","article-title":"Endothelial CD47 interaction with SIRPgamma is required for human T-cell transendothelial migration under shear flow conditions in vitro","volume":"112","author":"Stefanidakis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2025.189294_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732530","article-title":"SIRP\u03b3-CD47 interaction positively regulates the activation of human T cells in situation of chronic stimulation","volume":"12","author":"Dehmani","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0165","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.4049\/jimmunol.173.4.2562","article-title":"Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family","volume":"173","author":"Brooke","year":"2004","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0170","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s100380070013","article-title":"Molecular cloning of a novel human gene (SIRP-B2) which encodes a new member of the SIRP\/SHPS-1 protein family","volume":"45","author":"Ichigotani","year":"2000","journal-title":"J. Hum. Genet."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189294_bb0175","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009712","article-title":"The thrombospondins","volume":"3","author":"Adams","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0180","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.matbio.2012.01.005","article-title":"The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47","volume":"31","author":"Roberts","year":"2012","journal-title":"Matrix Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0185","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1161\/01.RES.0000115555.05668.93","article-title":"Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo","volume":"94","author":"Calzada","year":"2004","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-016-0381-z","article-title":"Is CD47 an innate immune checkpoint for tumor evasion?","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0195","first-page":"C201","article-title":"CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes","volume":"321","author":"Roberts","year":"2021","journal-title":"Am. J. Phys. Cell Phys."},{"issue":"33","key":"10.1016\/j.bbcan.2025.189294_bb0200","doi-asserted-by":"crossref","first-page":"29637","DOI":"10.1074\/jbc.M500922200","article-title":"CD47 augments Fas\/CD95-mediated apoptosis","volume":"280","author":"Manna","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0205","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.4049\/jimmunol.170.7.3544","article-title":"The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase a","volume":"170","author":"Manna","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2025.189294_bb0210","unstructured":"N.-h. Guo, V.S. Zabrenetzky, L. Chandrasekaran, J.M. Sipes, J. Lawler, H.C. Krutzsch, D.D. Roberts, Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1, Cancer Res. 58(14) (1998) 3154\u20133162."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189294_bb0215","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2020005382","article-title":"Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets","volume":"137","author":"Aburima","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0220","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1074\/jbc.M804860200","article-title":"Differential interactions of thrombospondin-1,-2, and-4 with CD47 and effects on cGMP signaling and ischemic injury responses","volume":"284","author":"Isenberg","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0225","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2004-09-3585","article-title":"Type 3 repeat\/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47\/alphavbeta3 in promyelocytic leukemia NB4 cells","volume":"106","author":"Saumet","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189294_bb0230","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0300-9084(03)00129-9","article-title":"Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release","volume":"85","author":"Roue","year":"2003","journal-title":"Biochimie"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0235","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.matbio.2010.12.004","article-title":"Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47","volume":"30","author":"Frazier","year":"2011","journal-title":"Matrix Biol."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189294_bb0240","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1128\/MCB.02116-06","article-title":"Drp1 mediates caspase-independent type III cell death in normal and leukemic cells","volume":"27","author":"Bras","year":"2007","journal-title":"Mol. Cell. Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0245","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1513\/AnnalsATS.202009-1115SD","article-title":"The ARREST pneumonia clinical trial","volume":"18","author":"Levitt","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0250","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cvr\/cvw218","article-title":"TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction","volume":"113","author":"Rogers","year":"2017","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0255","doi-asserted-by":"crossref","first-page":"3ra7","DOI":"10.1126\/scitranslmed.3000139","article-title":"Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling","volume":"1","author":"Maxhimer","year":"2009","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0260","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.kint.2016.03.034","article-title":"CD47 regulates renal tubular epithelial cell self-renewal and proliferation following renal ischemia reperfusion","volume":"90","author":"Rogers","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbcan.2025.189294_bb0265","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/srep01673","article-title":"Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors","volume":"3","author":"Kaur","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2025.189294_bb0270","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fendo.2018.00129","article-title":"The role for Myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues","volume":"9","author":"Goetzman","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0275","doi-asserted-by":"crossref","first-page":"E439","DOI":"10.1152\/ajpendo.00006.2013","article-title":"Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation","volume":"305","author":"Kong","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0280","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0285","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","article-title":"RGD and other recognition sequences for integrins","volume":"12","author":"Ruoslahti","year":"1996","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0290","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s004410100417","article-title":"Function and interactions of integrins","volume":"305","author":"Van der Flier","year":"2001","journal-title":"Cell Tissue Res."},{"issue":"6283","key":"10.1016\/j.bbcan.2025.189294_bb0295","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/346425a0","article-title":"Adhesion receptors of the immune system","volume":"346","author":"Springer","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189294_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gb-2007-8-5-215","article-title":"The integrins","volume":"8","author":"Takada","year":"2007","journal-title":"Genome Biol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189294_bb0305","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrm1736","article-title":"Tetraspanin functions and associated microdomains","volume":"6","author":"Hemler","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189294_bb0310","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1242\/jcs.114.20.3577","article-title":"Components of cell-matrix adhesions","volume":"114","author":"Zamir","year":"2001","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbcan.2025.189294_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7827-2-3","article-title":"Syndecans in tumor cell adhesion and signaling","volume":"2","author":"Beauvais","year":"2004","journal-title":"Reprod. Biol. Endocrinol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0320","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.1038\/ncb0402-e65","article-title":"Networks and crosstalk: integrin signalling spreads","volume":"4","author":"Schwartz","year":"2002","journal-title":"Nat. Cell Biol."},{"issue":"5473","key":"10.1016\/j.bbcan.2025.189294_bb0325","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189294_bb0330","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-007-7488-x","article-title":"Thrombospondins: from structure to therapeutics","volume":"65","author":"Isenberg","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0335","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/cancers13010080","article-title":"The ITIM-containing receptor: leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) modulates immune response and confers poor prognosis in invasive breast carcinoma","volume":"13","author":"Joseph","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0340","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1083\/jcb.135.2.533","article-title":"Thrombospondin modulates alpha v beta 3 function through integrin-associated protein","volume":"135","author":"Gao","year":"1996","journal-title":"J. Cell Biol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189294_bb0345","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1349-7006.2006.00245.x","article-title":"CD47 regulation of epithelial cell spreading and migration, and its signal transduction","volume":"97","author":"Shinohara","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2025.189294_bb0350","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/614619","article-title":"CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease","volume":"2013","author":"Oldenborg","year":"2013","journal-title":"ISRN Hematol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0355","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.matbio.2013.02.009","article-title":"Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation","volume":"32","author":"Miller","year":"2013","journal-title":"Matrix Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0360","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189294_bb0365","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0370","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer immunotherapy with immunomodulatory anti-CD137 and anti\u2013PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells","volume":"6","author":"S\u00e1nchez-Paulete","year":"2016","journal-title":"Cancer Discov."},{"issue":"5904","key":"10.1016\/j.bbcan.2025.189294_bb0375","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0380","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103+\/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0385","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0390","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.0105-2896.2009.00876.x","article-title":"Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation","volume":"234","author":"Dominguez","year":"2010","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0395","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/icb.2008.14","article-title":"Monocyte-derived dendritic cells in innate and adaptive immunity","volume":"86","author":"Leon","year":"2008","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bbcan.2025.189294_bb0400","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coi.2017.01.002","article-title":"Dendritic cells in cancer: the role revisited","volume":"45","author":"Veglia","year":"2017","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0405","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: an update","volume":"154","author":"Collin","year":"2018","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0410","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1084\/jem.20091627","article-title":"Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells","volume":"207","author":"Edelson","year":"2010","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0415","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.4049\/jimmunol.176.4.2161","article-title":"A major lung CD103 (alphaE)-beta7 integrin-positive epithelial dendritic cell population expressing Langerin and tight junction proteins","volume":"176","author":"Sung","year":"2006","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0420","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1084\/jem.176.1.47","article-title":"The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells","volume":"176","author":"Vremec","year":"1992","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0425","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.immuni.2012.04.012","article-title":"Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells","volume":"37","author":"Haniffa","year":"2012","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0430","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1084\/jem.20100348","article-title":"Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells","volume":"207","author":"Bachem","year":"2010","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0435","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1084\/jem.20092140","article-title":"Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens","volume":"207","author":"Jongbloed","year":"2010","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189294_bb0440","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2025.189294_bb0445","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0450","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.immuni.2017.02.019","article-title":"Dendritic cells display subset and tissue-specific maturation dynamics over human life","volume":"46","author":"Granot","year":"2017","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0455","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ni.2795","article-title":"Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation","volume":"15","author":"Vander Lugt","year":"2014","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0460","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2111909","article-title":"Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice","volume":"11","author":"Nath","year":"2022","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189294_bb0465","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189294_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117223","article-title":"Cord blood stem cell derived CD16(+) NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody","volume":"242","author":"Valipour","year":"2020","journal-title":"Life Sci."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189294_bb0475","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189294_bb0480","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-18-3267","article-title":"CD47-targeted near-infrared Photoimmunotherapy for human bladder cancer","volume":"25","author":"Kiss","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189294_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9100139","article-title":"CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth","volume":"9","author":"Golubovskaya","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0490","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI81603","article-title":"CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer","volume":"126","author":"Weiskopf","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0495","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/jclinpath-2020-206611","article-title":"Clinicopathological significance of CD47 expression in hepatocellular carcinoma","volume":"74","author":"Kim","year":"2021","journal-title":"J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0500","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1397248","article-title":"Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma","volume":"7","author":"Wu","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2025.189294_bb0505","first-page":"994","article-title":"Identification of Schlafen-11 as a target of CD47 signaling that regulates sensitivity to ionizing radiation and topoisomerase inhibitors, front","volume":"9","author":"Kaur","year":"2019","journal-title":"Oncol"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189294_bb0510","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-18-3125","article-title":"Extracellular matrix protein tenascin C increases phagocytosis mediated by CD47 loss of function in glioblastoma","volume":"79","author":"Ma","year":"2019","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0515","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.16548","article-title":"CD14(+) CD16(+) monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy","volume":"190","author":"Storti","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0520","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1038\/s41467-020-18245-7","article-title":"Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells","volume":"11","author":"Candas-Green","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0525","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.bbcan.2025.189294_bb0530","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","article-title":"Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy","volume":"118","author":"Chao","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189294_bb0535","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2025.189294_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110255","article-title":"The CD47-SIRPalpha axis is a promising target for cancer immunotherapies","volume":"120","author":"Hao","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189294_bb0545","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0550","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","article-title":"Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity","volume":"70","author":"Wang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189294_bb0555","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003464","article-title":"Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity","volume":"9","author":"Chen","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0560","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ymthe.2016.11.006","article-title":"Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies","volume":"25","author":"Dheilly","year":"2017","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0565","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/imt-2016-0135","article-title":"Tumor-associated macrophages: implications in cancer immunotherapy","volume":"9","author":"Petty","year":"2017","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0570","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12943-019-1102-3","article-title":"Harnessing tumor-associated macrophages as aids for cancer immunotherapy","volume":"18","author":"Li","year":"2019","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0575","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1412910","article-title":"Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects","volume":"7","author":"Yang","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2025.189294_bb0580","article-title":"The differential expression of CD47 may be related to the pathogenesis from myelodysplastic syndromes to acute myeloid leukemia","volume":"12","author":"Yan","year":"2022","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0585","first-page":"2111","article-title":"TLR3 agonism augments CD47 inhibition in acute myeloid leukemia","volume":"109","author":"Ramsey","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0590","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V90.7.2555","article-title":"Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines","volume":"90","author":"Ailles","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0595","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0600","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1532","article-title":"CD47 overexpression is related to tumour-associated macrophage infiltration and diffuse large B-cell lymphoma progression","volume":"14","author":"Shen","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189294_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102042","article-title":"Immunotherapy in Hodgkin and non-Hodgkin lymphoma: innate, adaptive and targeted immunological strategies","volume":"88","author":"Tun","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0610","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2025.189294_bb0615","article-title":"CD47 promotes tumor invasion and metastasis in non-small cell lung cancer","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0620","first-page":"3249","article-title":"High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis","volume":"18","author":"Yuan","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbcan.2025.189294_bb0625","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12935-019-0957-0","article-title":"Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients","volume":"19","author":"Yuan","year":"2019","journal-title":"Cancer Cell Int."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189294_bb0630","doi-asserted-by":"crossref","first-page":"8147","DOI":"10.18632\/oncotarget.2385","article-title":"Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients","volume":"5","author":"Baccelli","year":"2014","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189294_bb0635","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/jnr.22076","article-title":"Neurovascular effects of CD47 signaling: promotion of cell death, inflammation, and suppression of angiogenesis in brain endothelial cells in vitro","volume":"87","author":"Xing","year":"2009","journal-title":"J. Neurosci. Res."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0640","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1476-5381.2012.02099.x","article-title":"CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest","volume":"167","author":"Sick","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"36","key":"10.1016\/j.bbcan.2025.189294_bb0645","doi-asserted-by":"crossref","first-page":"26069","DOI":"10.1074\/jbc.M605040200","article-title":"CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1","volume":"281","author":"Isenberg","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189294_bb0650","article-title":"Targeting CD47 as a novel immunotherapy for breast cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189294_bb0655","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189294_bb0660","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-319-95294-9_5","article-title":"Microenvironment influences cancer cell mechanics from tumor growth to metastasis","volume":"1092","author":"Ghosh","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189294_bb0665","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nm.3965","article-title":"CD47 blockade as another immune checkpoint therapy for cancer","volume":"21","author":"Vonderheide","year":"2015","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0670","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/bjc.2017.173","article-title":"CD47 overexpression is associated with decreased neutrophil apoptosis\/phagocytosis and poor prognosis in non-small-cell lung cancer patients","volume":"117","author":"Barrera","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0675","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0680","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cjp2.309","article-title":"CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis","volume":"9","author":"Chen","year":"2023","journal-title":"J. Pathol. Clin. Res."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189294_bb0685","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1158\/1078-0432.CCR-14-1399","article-title":"Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms","volume":"21","author":"Cioffi","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0690","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.canlet.2015.02.036","article-title":"Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma","volume":"360","author":"Xiao","year":"2015","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189294_bb0695","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1091\/mbc.e04-01-0019","article-title":"Promotion of neurite and filopodium formation by CD47: roles of integrins, Rac, and Cdc42","volume":"15","author":"Miyashita","year":"2004","journal-title":"Mol. Biol. Cell"},{"issue":"48","key":"10.1016\/j.bbcan.2025.189294_bb0700","doi-asserted-by":"crossref","first-page":"12397","DOI":"10.1523\/JNEUROSCI.3981-06.2006","article-title":"CD47 promotes neuronal development through Src- and FRG\/Vav2-mediated activation of Rac and Cdc42","volume":"26","author":"Murata","year":"2006","journal-title":"J. Neurosci."},{"issue":"Pt 22","key":"10.1016\/j.bbcan.2025.189294_bb0705","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1242\/jcs.00119","article-title":"Thrombospondin-1 differentially induces chemotaxis and DNA synthesis of human venous smooth muscle cells at the receptor-binding level","volume":"115","author":"Lymn","year":"2002","journal-title":"J. Cell Sci."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0710","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189294_bb0715","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1074\/jbc.273.10.5670","article-title":"Phosphorylation of inositol 1,4,5-trisphosphate receptors by cAMP-dependent protein kinase. Type I, II, and III receptors are differentially susceptible to phosphorylation and are phosphorylated in intact cells","volume":"273","author":"Wojcikiewicz","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0720","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/0008-5472.CAN-07-6163","article-title":"Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy","volume":"68","author":"Zeng","year":"2008","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0725","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3727\/096504018X15155538502359","article-title":"CD47 promotes human glioblastoma invasion through activation of the PI3K\/Akt pathway","volume":"27","author":"Liu","year":"2019","journal-title":"Oncol. Res."},{"issue":"07","key":"10.1016\/j.bbcan.2025.189294_bb0730","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin. Med. J."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0735","first-page":"807","article-title":"Rectal cancer, version 6.2020: featured updates to the NCCN guidelines","volume":"18","author":"Benson","year":"2020","journal-title":"JNCCN J. Natl. Comprehens. Cancer Netw."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0740","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189294_bb0745","article-title":"Multifunctional nanodrug-mediated immunotherapy in microsatellite stable colorectal cancer via promoting m6A modification and M1-like tumor-associated macrophages polarization","volume":"2400100","author":"Li","year":"2024","journal-title":"Small Struct."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0750","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1038\/s41467-023-42303-5","article-title":"Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination","volume":"14","author":"Chou","year":"2023","journal-title":"Nat. Commun."},{"issue":"34","key":"10.1016\/j.bbcan.2025.189294_bb0755","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.19.00915","article-title":"High-dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing sarcoma with pulmonary metastases: results of the European Ewing tumour working initiative of National Groups, 99 trial and EWING 2008","volume":"37","author":"Dirksen","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189294_bb0760","doi-asserted-by":"crossref","first-page":"15207","DOI":"10.1002\/cam4.6208","article-title":"Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma","volume":"12","author":"Shulman","year":"2023","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0765","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2025.189294_bb0770","series-title":"TK216 for Relapsed\/Refractory Ewing Sarcoma: Interim Phase 1\/2 Results","author":"Ludwig","year":"2021"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0775","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/onc.2017.378","article-title":"Protein phosphatase 1 regulatory subunit 1A in Ewing sarcoma tumorigenesis and metastasis","volume":"37","author":"Luo","year":"2018","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.bbcan.2025.189294_bb0780","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-14-0072","article-title":"Reversible LSD1 inhibition interferes with global EWS\/ETS transcriptional activity and impedes Ewing sarcoma tumor growth","volume":"20","author":"Sankar","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0785","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28073","article-title":"Phase 1\/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory\/recurrent solid tumors including Ewing sarcoma: a Children\u2019s oncology group phase 1 consortium study (ADVL1411)","volume":"67","author":"Schafer","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bbcan.2025.189294_bb0790","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fped.2014.00083","article-title":"Targeting glutathione S-transferase M4 in Ewing sarcoma","volume":"2","author":"Zhuo","year":"2014","journal-title":"Front. Pediatr."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0795","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","article-title":"Macrophages, innate immunity and cancer: balance, tolerance, and diversity","volume":"22","author":"Mantovani","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189294_bb0800","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"22","key":"10.1016\/j.bbcan.2025.189294_bb0805","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-22-1471","article-title":"Ewing sarcoma and osteosarcoma have distinct immune signatures and intercellular communication networks","volume":"28","author":"Cillo","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189294_bb0810","doi-asserted-by":"crossref","unstructured":"T. Fujiwara, J.-i. Fukushi, S. Yamamoto, Y. Matsumoto, N. Setsu, Y. Oda, H. Yamada, S. Okada, K. Watari, M. Ono, Macrophage infiltration predicts a poor prognosis for human Ewing sarcoma, Am. J. Pathol. 179(3) (2011) 1157\u20131170.","DOI":"10.1016\/j.ajpath.2011.05.034"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0815","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/s41598-018-38127-9","article-title":"In-depth characterization of monocyte-derived macrophages using a mass cytometry-based phagocytosis assay","volume":"9","author":"Schulz","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0820","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","article-title":"Calreticulin and cancer","volume":"31","author":"Fucikova","year":"2021","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189294_bb0825","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.ajpath.2012.01.042","article-title":"Aberrant calreticulin expression is involved in the dedifferentiation of dedifferentiated liposarcoma","volume":"180","author":"Hisaoka","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0830","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13046-024-03093-w","article-title":"Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: turning \u201ctwo keys\u201d simultaneously","volume":"43","author":"Luo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189294_bb0835","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/RLI.0000000000001030","article-title":"Novel clinically translatable iron oxide nanoparticle for monitoring anti-CD47 cancer immunotherapy","volume":"59","author":"Roudi","year":"2024","journal-title":"Investig. Radiol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189294_bb0840","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0845","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrc3171","article-title":"Programmed cell removal: a new obstacle in the road to developing cancer","volume":"12","author":"Chao","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189294_bb0850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile","volume":"13","author":"Kauder","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbcan.2025.189294_bb0855","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136607","article-title":"Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study","volume":"136","author":"Patel","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189294_bb0860","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189294_bb0865","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.celrep.2018.07.062","article-title":"Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion","volume":"24","author":"Liu","year":"2018","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189294_bb0870","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189294_bb0875","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003464","article-title":"Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity","volume":"9","author":"Chen","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0880","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/thy.2018.0555","article-title":"Targeting CD47 in anaplastic thyroid carcinoma enhances tumor phagocytosis by macrophages and is a promising therapeutic strategy","volume":"29","author":"Sch\u00fcrch","year":"2019","journal-title":"Thyroid"},{"issue":"605","key":"10.1016\/j.bbcan.2025.189294_bb0885","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg8693","article-title":"Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189294_bb0890","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0822-6","article-title":"Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer","volume":"12","author":"Pan","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0895","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bbrc.2018.12.175","article-title":"CD47\/SIRP\u03b1 blocking enhances CD19\/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies","volume":"509","author":"Xu","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0900","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.drudis.2020.11.003","article-title":"The development of small-molecule inhibitors targeting CD47","volume":"26","author":"Yu","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbcan.2025.189294_bb0905","first-page":"5494","article-title":"Structural analysis and binding sites of inhibitors targeting the CD47\/SIRP\u03b1 interaction in anticancer therapy, computational and structural","volume":"19","author":"Huang","year":"2021","journal-title":"Biotechnol. J."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0910","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","article-title":"Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication","volume":"28","author":"Theruvath","year":"2022","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189294_bb0915","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002022","article-title":"Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer","volume":"9","author":"Cao","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189294_bb0920","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000905","article-title":"CD47\/SIRP\u03b1 blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0925","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.it.2010.04.001","article-title":"Macrophages as mediators of tumor immunosurveillance","volume":"31","author":"Jaiswal","year":"2010","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbcan.2025.189294_bb0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0935","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189294_bb0940","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12081235","article-title":"CD24: a novel target for cancer immunotherapy","volume":"12","author":"Panagiotou","year":"2022","journal-title":"J. Pers. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb0945","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","article-title":"A timeline of tumour-associated macrophage biology","volume":"23","author":"Cassetta","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"7769","key":"10.1016\/j.bbcan.2025.189294_bb0950","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189294_bb0955","first-page":"3928","article-title":"Blockade of the CD47\/SIRP\u03b1 checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab","volume":"109","author":"Biedermann","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0960","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1038\/s41467-024-49825-6","article-title":"An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189294_bb0965","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody\u2013drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189294_bb0970","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb0975","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304985","article-title":"Blockade of SIRP\u03b1-CD47 axis by anti-SIRP\u03b1 antibody enhances anti-tumor activity of DXd antibody-drug conjugates","volume":"19","author":"Sue","year":"2024","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbcan.2025.189294_bb0980","article-title":"A novel anti-CD47 protein antibody and toll-like receptor agonist complex detects tumor surface CD-47 changes in early stage lung cancer by in vivo imaging","volume":"133322","author":"Xu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189294_bb0985","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189294_bb0990","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1748322","article-title":"Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody","volume":"12","author":"Wang","year":"2020","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189294_bb0995","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1080\/19420862.2015.1062192","article-title":"A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells","volume":"7","author":"Piccione","year":"2015","journal-title":"MAbs"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189294_bb1000","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/1535-7163.MCT-17-1095","article-title":"Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia","volume":"17","author":"Buatois","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189294_bb1005","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood-2019-125363","article-title":"A phase I study of CC-90002, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory (R\/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS): final results","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189294_bb1010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153550","article-title":"Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbcan.2025.189294_bb1015","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6156757","article-title":"CD47 blockade inhibits tumor progression through promoting phagocytosis of tumor cells by M2 polarized macrophages in endometrial cancer","volume":"2018","author":"Gu","year":"2018","journal-title":"J Immunol Res"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189294_bb1020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004794","article-title":"TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis","volume":"10","author":"Brauneck","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189294_bb1025","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood-2021-148075","article-title":"Blockade of Tigit on AML-derived M2 macrophages results in reprograming into the M1 phenotype and enhances CD47-mediated phagocytosis","volume":"138","author":"Brauneck","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189294_bb1030","first-page":"1308","article-title":"IGF2BP3 enhances the growth of hepatocellular carcinoma tumors by regulating the properties of macrophages and CD8+ T cells in the tumor microenvironment","volume":"11","author":"Ma","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.bbcan.2025.189294_bb1035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.768115","article-title":"Significance of CD47 and its association with tumor immune microenvironment heterogeneity in ovarian cancer","volume":"12","author":"Yu","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:10:44Z","timestamp":1742296244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":207,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0304419X25000368"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189294","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD47 as a potent target in cancer immunotherapy: A review","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189294"}}